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INTRODUCTION
Breast cancer (BC) represents 25% of all cancer diagnoses and is the fifth most common cause of death in women worldwide. Approximately 80% of BCs are positive for estrogen receptor expression (ER+ tumours) and are treated with anti-estrogen (AE) adjuvant therapies such as tamoxifen or fulvestrant. Despite the clear benefit of these drugs at reducing tumour recurrence, de novo or acquired resistance often occurs (Pan et al., 2017) .
Cancer Stem Cells (CSCs) are a cellular population endowed with self-renewal properties, which are responsible for tumour progression and metastasis (Reya et al., 2001) . Aldehyde Dehydrogenase (ALDH) activity is reported to be a CSC marker in human BC cells (Ginestier et al., 2007) . ALDH+ cells are ERnegative, and likely to be resistant to the direct effects of AE therapy (Honeth et al., 2014) . We have previously established that ALDH+ cells drive therapeutic resistance in ER+ BC tumours (Simoes et al., 2015) .
Intra-tumour heterogeneity within BCs hinders accurate diagnosis and effective treatment. Understanding of the cellular diversity within the CSC population, especially at the single cell level, is limited. Given the importance of ALDH+ cells in promoting AE resistance, we investigated the gene expression pattern of this cellular population at the single cell level. This study reveals a previously uncharacterised level of heterogeneity within AE resistant CSCs, and identifies IL1R1 as a potential target in refractory and dormant BCs.
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RESULTS
ALDH+ cells from AE-treated ER+ BCs have greater breast CSC activity than
ALDH-cells
Previous research reported by our group (Simoes et al., 2015) established that AE treatment of BC Patient-Derived Xenograft (PDX) tumours in mice enriches for breast CSCs (BCSCs) with high ALDH enzymatic activity. To further investigate this AE resistant population, we isolated ALDH+ and ALDH-cells from 8 metastatic ER+ BCs undergoing AE therapies. There was significant inter-individual variation in the percentage of ALDH+ cells (range 0.32%-27.3%) ( Figures 1A and S1A) . Importantly, ALDH+ cells exhibited significantly greater BCSC activity as assessed by mammosphere formation than ALDH-cells in 7 out of 8 patient samples, and in 4 of these samples the mammosphere forming efficiency (MFE) was increased by more than 3-fold ( Figure 1B) . On average, ALDH+ cells from the 8 metastatic BC samples showed 3.8-fold greater MFE than ALDH-cells (p=0.001) ( Figure 1C) . Next, we investigated the in vivo tumour-initiating capabilities of ALDH+ cells isolated from the ER+ cell line MCF-7, following 6-day in vitro treatment with the AEs tamoxifen or fulvestrant ( Figure 1D) . Injection of 1,000 ALDH+ cells consistently gave rise to bigger tumours compared to the same number of ALDH-cells significantly so in tamoxifen and fulvestrant-treated cells (Figure 1E ). This suggests a cytostatic effect of these drugs which acts specifically on the ALDH-cell population.
Extreme Limiting Dilution Analysis (ELDA) revealed that on average the number of tumour-initiating cells was 4.2-fold higher in ALDH+ compared to the non-BCSC ALDH-cells in all three conditions tested ( Figure 1F) . As few as 100 ALDH+ cells gave rise to tumours in mice whereas 100 ALDH-cells failed to do 6 so. These results highlight the increased tumour-initiating capabilities of the ALDH+ population in comparison to ALDH-cells, implying the need to characterize this population of CSCs that survive AE therapies.
Transcriptomic characterisation of ALDH+ cells in therapy resistant patient samples To better understand the development of resistance to AE therapies in ER+ BC patients, we interrogated and compared the gene expression pattern between ALDH+ and ALDH-cells in 9 metastatic ER+ patient samples (Figure 2A) .
Overall, 599 genes were found to be differentially expressed (p≤0.05) between the two cell populations amongst the 18,752 genes with measured expression (Table S1 ).
In order to identify which isoforms of ALDH are responsible for the Aldefluor activity of ALDH+ cells in AE resistant ER+ patient samples, we investigated the mRNA expression levels of the 18 detected ALDH isoforms in our patient sample dataset. ALDH1A1 and ALDH1A3 showed the greatest fold change (FC) between ALDH+ and ALDH-cells with a mean FC higher than 2 ( Figure   2B ). Validation by qRT-PCR confirmed the elevated expression of ALDH1A1 and ALDH1A3 isoforms in the ALDH+ compared to ALDH-population, with a considerably higher averaged linear FC of ALDH1A3 (300-fold) than ALDH1A1 (19-fold) across the 9 patient samples ( Figure 2C) . Interestingly, we also found that 6-days of AE treatment significantly up-regulated ALDH1A3 mRNA levels in two ER+ cell lines, MCF-7 and T47D ( Figure S2A) . Therefore, we used a doxycycline-inducible shRNA system to test the effects of ALDH1A3 silencing on AE resistance. ALDH1A3 was stably down-regulated by 58% compared with 7 transfected cells not exposed to doxycycline, and there was a significant decrease in the induction of ALDH1A3 mRNA levels following AE treatment in the knockdown (KD) cells (Figure 2D , left). The enrichment in the ALDH+ cell population after tamoxifen and fulvestrant treatments was significantly reduced in the ALDH1A3KD cells (Figure 2D, right) , indicating the importance of the ALDH1A3 isoform in ALDH+ cell population after AE therapy.
We also interrogated the gene expression profile of ALDH+ and ALDHpopulations from AE-treated MCF-7 cells. The meta-analysis from the patient and cell line microarray datasets (FC≥±1.5 and p≤0.05) revealed 100 genes commonly shared between ALDH+ cells of patient samples and ALDH+ cells of the MCF-7 cell line (Figure 2E , Table S2 ). Ingenuity Pathway Analysis (IPA) for these genes predicted activation of eight upstream regulators (z-score ≥2.5), including several cytokines; for example, interleukin-1 beta (IL1, Figure S2B ).
Of the 100 genes identified in the ALDH+ cell population, 15 were predicted to be regulated by IL1, and these were all up-regulated in the ALDH+ cells which is consistent with activation of IL1 signalling (Figure 2F) . One of these genes was interleukin-1 receptor type 1 (IL1R1), which binds and transmits the signal of both IL1 and IL1.
AE treatment selects for IL1R1-expressing ALDH+ cells
To study the effects of AE treatment on the ALDH+ population at the single cell level, we analysed the expression of IL1R1 and ALDH1A3 in 178 individual ALDH+ cells following tamoxifen or fulvestrant treatment. For this purpose we combined flow cytometry, the single cell C1 system and the Biomark HD technology. Sorted ALDH+ cells were injected and captured in the C1 system, 8 followed by microscopic examination of cell singlets ( Figure 3A) . When comparing IL1R1 gene expression profiles between control and AE-treated ALDH+ cells, we observed that gene expression levels of IL1R1 increased significantly following tamoxifen and fulvestrant treatment (Figures 3B-3C) . In contrast ALDH1A3 expression is high in nearly all ALDH+ cells, with or without therapy, as expected (Figures 3B-3C ). IL1R1 gene expression density plots revealed that control ALDH+ cells match a bimodal distribution with two distinct transcriptomic states: a population that comprises the majority of cells, which show none or very low IL1R1 gene expression levels, and a small population of cells showing high IL1R1 levels. However, following AE therapy the vast
majority of ALDH+ cells show high IL1R1 gene expression levels (Figures 3C
and S3). These results reveal the existence of cellular diversity within the ALDH+ population that can be unravelled by single-cell gene expression profiling, and highlight IL1R1 as an important gene in AE resistant BCSCs. To determine the clinical significance of identifying IL1R1 as facilitating AE resistance, we assessed IL1R1 gene expression levels in patient breast tumours. Consistent with our cell line data, we found IL1R1 gene expression levels to be increased in breast tumors following short-term administration of fulvestrant to patients (Figure 3D , Patani et al., 2014) . In addition, we observed that IL1R1 expression was significantly increased upon short and long term aromatase inhibitor (AI) treatment compared to baseline levels in four different patient cohorts totalling 404 patients (Ellis et al., 2017; Dunbier et al., 2013; Turnbull et al., 2015) (Figure 3E) . Notably, we also found that elevated expression of IL1R1 in ER+ patients who had been treated with AI for 2 weeks was significantly associated with poor outcome (Figure 3F) . 9 Single-cell RNA profiling identifies a dormant ALDH+ population that is expanded after AE treatment IL1R1 and ALDH1A3 single-cell gene expression revealed heterogeneity within ALDH+ cells, therefore we decided to investigate the existence of putative subpopulations within the ALDH+ cell population. We examined the mRNA expression level of 68 genes across 444 single ALDH+ MCF-7 cells following control, tamoxifen or fulvestrant treatment. The 68-gene list ( Table S3) comprised key regulators associated with stemness, self-renewal pathways and markers related to ALDH+ cells that were identified in the whole gene expression data set ( Figure 2 ). A Gaussian Mixture Model approach to estimate and assign clusters to the cells predicted the existence of seven different cellular ALDH+ populations (Control 1 and 2, Tamoxifen 3 and 4, Fulvestrant 5, 6 and 7) ( Figure 4A ). Some of these initial clusters were merged based on their gene expression similarities using Ward's Hierarchical clustering on Euclidean distance coupled with bootstrapping to estimate branch robustness. This analysis resulted in two major populations of cells, population A and population B which were both made of clusters from the three different treatments, and a small population of Fulvestrant-treated cells (Fulvestrant-7) that were distinct from the rest of the cells (Figure 4B ). Next, we applied Discriminant Analysis of Principal Components (DAPC) for graphical representation of these three distinct populations ( Figure 4C) . The 8 genes most associated with the first linear discriminant had the highest contribution to the separation of population B from the other populations ( Figure 4D) . Genes associated with cell proliferation, for example the cycle regulator CCND1 and protein kinase AKT1, were downregulated in population B compared to population A, whereas the expression of the mesenchymal marker SNAI2 was higher in the former ( Figure   4E ). Moreover, population A, which comprised the vast majority of the ALDH+ cells analysed (82%), exhibited higher expression of proliferative markers PCNA and KI67 in comparison to population B (Figure S4A) . Interestingly, only 10% of the non-treated ALDH+ cells belonged to the quiescent population B, however following tamoxifen and fulvestrant treatment the percentage of quiescent cells represented 44% and 19% of the total cells, respectively ( Figure   4F ). A recent study (Selli et al., 2019) investigated gene expression changes of dormant and acquired resistant ER+ tumours treated with an AI for more than 4 months. Notably, ALDH1A1 and ALDH1A3 gene expression levels are significantly increased in dormant tumours compared to acquired resistant tumours which supports the existence of an ALDH+ dormant population after AE treatment ( Figure 4G ). Relative to pre-treatment the dormant tumours also had significantly increased expression of both ALDH1A1 and ALDH1A3 as well as IL1R1 and SNAI2, along with reduced CCND1 (Figure S4B ) consistent with the results above for the dormant population identified by single-cell analysis.
This data suggests that AE resistance can be driven by non-proliferative dormant ALDH+ cells and supports a potential role for IL1R1-targeted therapy to overcome resistance in ER+ BCs (Figure 4H ).
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DISCUSSION
Previously, we reported that ALDH+ cells are resistant to AE therapy and that high ALDH1 expression predicts resistance in women treated with tamoxifen (Simões et al., 2015) . Our findings here establish a role for the IL1R1 signalling pathway in the regulation of AE resistant ALDH+ BCSCs. We also identify heterogeneity in the ALDH+ cell population and an expansion of a quiescent ALDH+ sub-population after AE therapies.
Firstly, we showed that BC cells treated with AEs contain a population of ALDH+ cells that have higher mammosphere-forming and tumour-initiating cell frequency than ALDH-cells. We next wanted to further characterize these cells and the mechanisms that drive them. ALDH1A1 and ALDH1A3 isoforms are both reported to be predictive biomarkers of poor clinical outcome in BC (Liu et al., 2014; Marcato et al., 2011) , and we found them to be the most highly increased among 18 ALDH isoforms detected in metastatic patient-derived ALDH+ BC cells. ALDH1A3 knock down confirmed that this isoform is crucial for enriching the ALDH+ population following AE treatment. This data supports the growing body of literature describing the involvement of ALDH1A3 in cancer stemness, tumour progression and poor prognosis.
We found that ALDH+ cells have a different gene expression profile compared to ALDH-cells in both ER+ metastatic patient samples and MCF-7 cells. In particular, genes that predicted activation of pro-inflammatory cytokine IL1 signalling, including IL1R1, were expressed at higher levels in ALDH+ cells. By using single-cell gene expression profiling in the ALDH+ cell population we identified IL1R1 to be significantly up-regulated in AE resistant ALDH+ cells compared to control cells. Importantly, we found that expression of IL1R1 is 12 induced in the tumours of patients treated with AE therapies and predicts for treatment failure. This data indicates that IL1 signalling is likely to be important for CSCs to drive AE resistance in BC. IL1 expression correlates with increased aggressiveness and enhanced metastatic potential of BC cells, suggesting IL1 as a potential biomarker for predicting which patients are likely to be diagnosed with BC metastasis, specifically to bone (Tulotta et al., 2019) .
Single-cell targeted transcriptome analysis revealed the existence of distinct clusters within ALDH+ cells and the expansion of a quiescent ALDH+ population (Population B) after AE therapies. Heterogeneity within BCSCs of MCF-7 cells has previously been described using different CSC functional assays, such as mammospheres, growth in hypoxia and PKH26 retention, to isolate single cells for gene expression analysis (Akrap et al., 2016) . Our data suggests that Population B represents a small population of non-dividing quiescent ALDH+ cells that survive AE treatments, which may enable them to survive for long periods of time and eventually lead to late recurrence in ER+ BC patients. This idea is supported by data from AI-induced dormant tumours that express increased levels of ALDH1A1 and ALDH1A3 genes. Recently, single-cell RNA profiling of normal breast samples identified four cell clusters within the ALDH+ cell population (Colacino et al., 2018) . Interestingly, Population B resembles cluster 3 identified in this publication, which was characterized by high expression of mesenchymal markers, including SNAI2, and low expression of proliferative genes, such as KI67, PCNA, CCND1.
Population B expresses low levels of AKT1 and AKT1 low cancer cells have been
reported to be quiescent cells that survive chemotherapy in breast tumours (Kabraji et al., 2017) .
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Combination therapies targeting both bulk tumour cells and BCSCs should reduce the probability of tumour relapse and, therefore, pharmacological inhibitors that target CSC pathways have been highly pursued and are being tested in patients (Brooks et al., 2015) . In our model, both proliferative and dormant AE resistant BCSCs express IL1R1. This suggests that anti-IL1R1 therapies, such as Anakinra (recombinant form of human IL-1 receptor antagonist) or Canakinumab (human anti-IL1 monoclonal antibody), could represent a new strategy to target AE-resistant CSCs.
In conclusion, the present work contributes to our understanding of the cellular heterogeneity present in the AE resistant BCSC population. Our work suggests that CSC dormancy is an adaptive strategy to evade AE treatments and supports targeting of ALDH+IL1R1+ cells to reverse AE resistance. This work highlights the advantages of single-cell transcriptomic analysis, rather than bulk tissue, to interrogate the cellular heterogeneity within the ALDH+ CSC population. Further understanding of the dormant ALDH+ population that survives AE therapies, particularly using clinical samples, will provide new insights for prevention and treatment of recurrences of ER+ BC.
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EXPERIMENTAL PROCEDURES
A comprehensive description of the methodology is included in the supplementary information.
Breast Cancer Samples
Consented, de-identified pleural effusion or ascitic fluids were collected at the Christie NHS Foundation Trust (UK) or the University of Michigan (USA). The clinico-pathological details of the samples are shown in Table S4 . 
Fold change ALDH+ vs ALDH-cells
Gene expression of ALDH isoforms
TetON-shALDH1A3 HER2  MKP1  TAZ   CDH3  HES1  MTOR  TGFB1   CTNNB1  HPRT1  MUC1  TGFBR1   CXCR1  ID1  NANOG  TP53   CXCR4  IGFBP5  NFKB1  TSPAN6   CYR61  IL1R1  NOTCH1  TWIST1   DLL1  IL6R  NOTCH2  UXT   ENAH  IL6ST  NOTCH3  YAP1   Table S3 . List of 68 genes used for single-cell targeted transcriptome analysis. 
Genes
ABCG2 EPCAM ITGA6 NUMB AKT1 ESR1 JAG1 PCNA ALDH1A3 EZH2 JAG2 PGR AR FBXW7 KRT18 PIK3CA BRCA1 GAPDH KRT19 POU5F1 CA12 GATA3 KRT8 RAB7A CCND1 GJA1 LIN28A SNAI2 CD24 GPRC5A MET SOCS3 CD44 GSK3B MKI67 SOX2 CDH1
Mammosphere Culture
Cells were counted and seeded at a density of 5,000 cells/well in 6-well plates containing mammosphere media (DMEM/F12 media with L-Glutamine (Gibco), B27 supplement (Gibco; 12587) and 20 ng/ml EGF (Sigma)) for 7 days at 37ºC.
Mammosphere forming efficiency (MFE) was calculated by dividing the number of mammospheres greater than 50µm by the number of cells seeded per well and is expressed as the mean percentage of MFE (Shaw et al., 2012) . manufacturer's guidelines. The GeneChip array was scanned using the Scanner 3000 system with autoloader (Affymetrix).
Microarray data from cell line and patient samples were processed using the Affy package in R (Gautier et al., 2004) . Data was quantile-normalised and Log2 transformed. Differential gene expression analysis was carried using paired Rank Products (Breitling et al., 2004) . Meta-analysis was performed using iPathwayGuide (AdvaitaBio). Statistical significance for RNA expression was assessed using t-test parametric testing.
Single-Cell Analysis
Data generated by the Biomark (Fluidigm) were converted into Log2 expression values and quality controls were undertaken. These included data filtering to remove all values under the limit of detection, which was set to threshold cycles (Ct) greater than 28; the removal of genes expressed in 3 or less cells within each treatment and, the removal of outliers (via the function identifyOutliers implemented in the R package FluidigmSC -Fluidigm Corporation, 2014).
Missing completely at random values were estimated and inputted using the R package MICE (Azur et al., 2011) . We undertook a statistical approach to eliminate doublets derived from equipment unfitness (Fluidigm Corporation, 2016) . Using the package Mclust in R we fitted Gaussian mixture models to identify cell clusters within each treatment. These models indicated the existence of two very well defined cell clusters in each condition. The nature of these clusters was further investigated by plotting the average Log2 expression per gene in both clusters, pointing towards a stratification into doublets and singlets. Clusters corresponding to singlets were taken forward for the analysis.
With the aim of identifying different cell populations we used a finite Gaussian 28 mixture model to (a) estimate the number of clusters within the data (function Mclust within the R package Mclust (Scrucca et al., 2016) ) and (b) generate those clusters. Ward hierarchical clustering with bootstrapping (Ward, 1963) was undertaken with the package pvclust in R to find similarities between clusters and merge smaller clusters into larger ones (threshold of Approximately Unbiased (AU) p-value greater than 0.9). Merged clusters were assessed for biases regarding batch and plate. Further analysis of cluster similarities and genes associated to cluster differences were undertaken using Discriminant Accession Numbers:
The Affymetrix data in this paper have been deposited in NCBI's Gene Expression Omnibus repository under series accession number GSE136287.
